The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

This kind of voluntary information that customers share directly with advertisers is known as zero-party data – and it has ...

In some ways, pharma connecting directly with patients isn’t novel at all: pharma companies in the United States have been ...

Under Kennedy's plan, the FDA is set to bear the brunt of the job losses, with 3,500 workers due to be shed, while the CDC is ...